QuickView for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=161EA4FB6A70DC430F4519468CC7F620;jsessionid=696890CAB45EBF2E3C87D2130F1D510F;jsessionid=DFECE6B915F61453DBC70F60C514FA19;jsessionid=CD1CA357D0C087BC529470552FBFA40B;jsessionid=A959B46D525313BD44022FFEF1B51E9E;jsessionid=8CA3875B4F741427EA74B60933B99D0C;jsessionid=EF568F38FD00654DB02821EB42D2EABC (gene)

1. Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm.
2. Clinical Evaluation of Cystic Renal Masses With Bosniak Classification by Contrast-Enhanced Ultrasou…
3. Feasibility of Surveillance for Mucinous Cystic Neoplasm of the Pancreas: A Multi-Institutional Retr…
4. Clinicopathological and genetic characteristics of congenital cystic adenomatoid malformation of lun…
5. The added value of contrast-enhanced ultrasound in evaluation of indeterminate small solid renal mas…

There were no clinical trials for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=161EA4FB6A70DC430F4519468CC7F620;jsessionid=696890CAB45EBF2E3C87D2130F1D510F;jsessionid=DFECE6B915F61453DBC70F60C514FA19;jsessionid=CD1CA357D0C087BC529470552FBFA40B;jsessionid=A959B46D525313BD44022FFEF1B51E9E;jsessionid=8CA3875B4F741427EA74B60933B99D0C;jsessionid=EF568F38FD00654DB02821EB42D2EABC